FDA
-
-
-
-
-
-
-
Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
-
-
-
-
-
-
-
Kamada receives tax ruling on dividend withholding procedures
-
-
-
-
-
-
-
Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026
-
-
-
-
-
-
-
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
-
-
-
-
-
-
-
Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas
-
-
-
-
-
-
-
Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders
-
-
-
-
-
-
-
Kamada Ltd. (KMDA) Announces a $25M 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America
-
328,335 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

